Prospective multicentre randomised clinical trial comparing survival rates, quality of life and nutritional status between advanced gastric cancer patients with different follow-up intensities: study protocol for the STOFOLUP trialopen access
- Authors
- Eom, Bang Wool; Koo, Dong-Hoe; An, Ji Yeong; Lee, Han Hong; Kim, Hyoung-Il; Hur, Hoon; Yoo, Moon-Won; Ryu, Min-Hee; Lee, Hyuk-Joon; Kim, Su Mi; Park, Ji-Ho; Min, Jae Seok; Seo, Kyung Won; Jeong, Sang-Ho; Jeong, Oh; Kwon, Oh Kyoung; Ryu, Seung Wan; Yoo, Chang Hak; Bae, Jae Moon; Ryu, Keun Won
- Issue Date
- Dec-2021
- Publisher
- BMJ PUBLISHING GROUP
- Keywords
- gastrointestinal tumours; protocols & guidelines; surgery
- Citation
- BMJ OPEN, v.11, no.12
- Indexed
- SCIE
SCOPUS
- Journal Title
- BMJ OPEN
- Volume
- 11
- Number
- 12
- URI
- https://scholarworks.bwise.kr/gnu/handle/sw.gnu/2936
- DOI
- 10.1136/bmjopen-2021-056187
- ISSN
- 2044-6055
- Abstract
- Introduction Patients who underwent curative gastrectorny for gastric cancer are regularly followed-up for the early detection of recurrence and postoperative symptom management. However, there is a lack of evidence with regard to proper surveillance intervals and diagnostic tools. This study aims to evaluate whether frequent surveillance tests have a survival benefit or improve the quality of life in patients who underwent curative resection for advanced gastric cancer. Methods and analysis The STOFOLUP trial is an investigator-initiated, parallel-assigned, multicentre randomised controlled trial involving 16 hospitals in the Republic of Korea. Patients (n=886) diagnosed with pathological stage II or III gastric adenocarcinoma will be randomised to either the 3-month or the 6-month group at a 1:1 ratio, stratified by trial site and tumour stage. Patients allocated to the 3-month group will undergo an abdominal CT scan every 3 months postoperatively and those allocated to the 6-month group will undergo CT every 6 months. The primary endpoint is 3-year overall survival and the secondary endpoints are quality of life, as assessed using KOrean QUality of life in Stomach cancer patients Study group-40, the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 and the stomach cancer-specific module (ST022), and nutritional outcomes. Other survival data including data concerning 3-year disease-free survival, recurrence-free survival, gastric cancer-specific survival and postrecurrence survival will also be estimated. The first patient was enrolled on July 2021 and active patient enrolment is currently underway. Ethics and dissemination This study has been approved by the Institutional Review Board of eight of the participating hospitals (NCC 2021-0085, KBSMC2021-01-059, SMC 2021-01-140, KC210EDE0082, 4-2021-0281, AJIRB-MED-INT-20-608, 2021-0515 and H-2102-093-1198). This study will be disseminated through peer-reviewed publications, national or international conferences.
- Files in This Item
- There are no files associated with this item.
- Appears in
Collections - College of Medicine > Department of Medicine > Journal Articles
![qrcode](https://api.qrserver.com/v1/create-qr-code/?size=55x55&data=https://scholarworks.gnu.ac.kr/handle/sw.gnu/2936)
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.